Regeneron aims to stop muscle loss with combination treatment approach in obesity

02 Feb 2024

Phase 2

Regeneron reiterated its plans to jump into the weight loss race in 2024, expecting to start testing a combination of its muscle-preserving drugs with semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy. The $105 billion New York biotech said it anticipates starting a Phase II study in mid-2024 that will test a range of different doses and combinations of semaglutide, trevogrumab (an anti-myostatin antibody) and garetosmab (an anti-activin A antibody). George Yancopoulos, Regeneron’s chief scientific officer, highlighted the loss of muscle as a concerning side effect of obesity treatments like Ozempic and Eli Lilly’s Zepbound.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Regeneron Pharmaceuticals, Inc.

Novo Nordisk A/S

Eli Orthodontics

[+1]

Indications

Obesity

Targets

Drugs

Semaglutide (Novo Nordisk)TrevogrumabStamulumab

[+2]

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.